Fate Therapeutics Inc (FATE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
J. Scott Wolchko
Employees:
500
3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
858.875.1803

Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.

Data derived from most recent annual or quarterly report
Market Cap 523.749 Million Shares Outstanding97.17 Million Avg 30-day Volume 3.404 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.86
Price to Revenue99.267 Debt to Equity0.0 EBITDA-198.548 Million
Price to Book Value8.1664 Operating Margin-388.55780000000004 Enterprise Value4.827 Billion
Current Ratio7.793 EPS Growth-0.067 Quick Ratio7.684
1 Yr BETA 1.7425 52-week High/Low 43.12 / 4.02 Profit Margin-379.8858
Operating Cash Flow Growth-315.1775 Altman Z-Score12.5563 Free Cash Flow to Firm -118.688 Million
Earnings Report2023-05-03
View SEC Filings from FATE instead.

View recent insider trading info

Fate Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FATE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FATE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-07 by WOLCHKO J SCOTT
  • 4: filed on 2023-02-07 by VALAMEHR BAHRAM
  • 4: filed on 2023-02-07 by TAHL CINDY
  • 4: filed on 2023-02-07 by POWL BRIAN T.
  • 4: filed on 2023-02-07 by DULAC EDWARD J III
  • 4: filed on 2023-02-07 by CHU YU-WAYE
  • 4: filed on 2023-01-20 by MENDLEIN JOHN
  • 4: filed on 2023-01-13 by MENDLEIN JOHN
  • 4: filed on 2023-01-13 by VALAMEHR BAHRAM
  • 4: filed on 2023-01-11 by WOLCHKO J SCOTT

    • Events (8k)

  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WOLCHKO J SCOTT PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-02-06 4

    TAHL CINDY GENERAL COUNSEL AND SECRETARY

    • Officer
    		 0 2023-02-06 3

    VALAMEHR BAHRAM CHIEF R&D OFFICER

    • Officer
    		 0 2023-02-06 5

    DULAC EDWARD J III CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-02-06 3

    CHU YU-WAYE CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-02-06 3

    POWL BRIAN T. CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-02-06 3

    MENDLEIN JOHN

    • Director
    		 311,231 2023-01-19 4

    PLAVSIC MARK CHIEF TECHNICAL OFFICER

    • Officer
    		 123,705 2023-01-10 2

    RASTETTER WILLIAM H

    • Director
    		 617,424 2022-06-09 1

    HERSHBERG ROBERT

    • Director
    		 22,552 2022-06-09 2

    COUGHLIN TIMOTHY

    • Director
    		 66,282 2022-06-09 2

    REDMILE GROUP, LLC

    GREEN JEREMY

    • Director
    • 10% Owner
    		 12,968,553 2022-06-09 1

    AGARWAL SHEFALI

    • Director
    		 22,383 2022-06-09 4

    LEE MICHAEL STEWART

    • Director
    		 23,224 2022-06-09 1

    JOOSS KARIN

    • Director
    		 21,741 2022-06-09 2

    XU YUAN

    • Director
    		 25,287 2022-06-09 1

    EPSTEIN ROBERT S

    • Director
    		 23,224 2021-06-09 0

    SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER

    • Officer
    		 73,020 2021-03-08 0

    NASHAT AMIR

    • Director
    		 2,310,432 2019-07-31 0

    ABBOT STEWART CHIEF DEVELOPMENT OFFICER

    • Officer
    		 64,917 2018-05-15 0

    STORGARD CHRIS CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-01-16 0

    ENYEDY MARK J

    • Director
    		 0 2017-05-02 0

    FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER

    • Officer
    		 103,816 2016-01-08 0

    WEYER CHRISTIAN SEE REMARKS

    • Officer
    • Director
    		 30,429 2015-04-13 0

    MULTANI PRATIK S CHIEF MEDICAL OFFICER

    • Officer
    		 3,024 2015-01-05 0

    FLYNN PETER D SEE REMARKS

    • Officer
    		 6,505 2015-01-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DULAC EDWARD J III - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 16:15:19 -0500 2023-02-06 A 425,000 a 425,000 direct

    TAHL CINDY - Officer GENERAL COUNSEL AND SECRETARY

    		2023-02-07 16:18:21 -0500 2023-02-06 A 425,000 a 425,000 direct

    POWL BRIAN T. - Officer CHIEF COMMERCIAL OFFICER

    		2023-02-07 16:16:46 -0500 2023-02-06 A 425,000 a 425,000 direct

    WOLCHKO J SCOTT - Director - Officer PRESIDENT AND CEO

    		2023-02-07 16:21:26 -0500 2023-02-06 A 500,000 a 500,000 direct

    VALAMEHR BAHRAM - Officer CHIEF R&D OFFICER

    		2023-02-07 16:20:09 -0500 2023-02-06 A 450,000 a 450,000 direct

    CHU YU-WAYE - Officer CHIEF MEDICAL OFFICER

    		2023-02-07 16:13:35 -0500 2023-02-06 A 425,000 a 425,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FATE THERAPEUTICS INC FATE 2023-03-24 22:15:03 UTC 4.4119 0.4081 1400000
    FATE THERAPEUTICS INC FATE 2023-03-24 21:45:03 UTC 4.4119 0.4081 1400000
    FATE THERAPEUTICS INC FATE 2023-03-24 21:15:03 UTC 4.4119 0.4081 1400000
    FATE THERAPEUTICS INC FATE 2023-03-24 20:45:03 UTC 4.4119 0.4081 1400000
    FATE THERAPEUTICS INC FATE 2023-03-24 20:15:04 UTC 4.4119 0.4081 1400000
    FATE THERAPEUTICS INC FATE 2023-03-24 19:45:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 19:15:04 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 18:45:04 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 18:15:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 17:45:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 17:15:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 16:45:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 16:15:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 15:45:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 15:15:03 UTC 4.4119 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 14:45:03 UTC 4.1619 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 14:15:03 UTC 4.1619 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 13:45:03 UTC 4.1619 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 13:15:04 UTC 4.1619 0.4081 1300000
    FATE THERAPEUTICS INC FATE 2023-03-24 12:45:03 UTC 4.1619 0.4081 1300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund FATE -1793.0 shares, $-65265.2 2020-08-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund FATE -75.0 shares, $-1665.75 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund FATE -22.0 shares, $-488.62 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund FATE -972.0 shares, $-88092.36 2021-01-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund FATE -1091.0 shares, $-60015.91 2021-11-30 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund FATE -8385.0 shares, $-175414.2 2022-10-31 N-PORT
    Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund FATE -2986.0 shares, $-62467.12 2022-10-31 N-PORT
    PACE SELECT ADVISORS TRUST- PACE Alternative Strategies Investments FATE -2454.0 shares, $-51337.68 2022-10-31 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- 361 Global Long/Short Equity Fund FATE -24191.0 shares, $-506075.72 2022-10-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF FATE -2240.0 shares, $-46636.8 2022-11-30 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Daniel Goldman House Filing 2023-02-09 2023-01-31 S $1,001-$15,000

    Elevate your investments